← Back to all trials
Recruiting
NCT06308510
Detection of Aneuploidy in Cell Free DNA to Improve the Sensitivity of Diagnostic Peritoneal Lavage in Gastric Cancer
Conditions: Gastric Cancer
Sex: All
Ages: 18 Years – N/A
Healthy volunteers: Yes
Enrollment: 63
Sponsor: Erasmus Medical Center
Location: Erasmus MC Rotterdam
Summary
Aneuploidy may be used as a more sensitive diagnostic tool to detect peritoneal metastasis compared to conventional cytology and imaging techniques. Our aim is to establish whether aneuploidy as detected in cfDNA (as a measure for ctDNA) in PLF of patients with GC may hold value as an additional staging and tumor evaluation method in GC patients.
Eligibility Criteria
Gastric cancer patients:
Inclusion Criteria:
* Age ≥18 years old;
* Written informed consent according to the ICH-GCP and national/local regula-tions.
Exclusion Criteria:
\- Language difficulty, dementia or altered mental status prohibiting the under-standing and giving of informed consent.
non-cancer controls:
Inclusion criteria:
* Operable patients who will undergo a planned diagnostic laparoscopy for a benign indication bariatric or gallbladder disease);
* Age ≥18 years old;
* Written informed consent according to the ICH-GCP and national/local regulations.
Exclusion criteria:
* Active inflammation or infection;
* Subjects with previous malignancies are excluded unless a complete remission was achieved at least 5 years prior to study entry (exceptions include but are not limited to, non-melanoma skin cancers; in situ bladder cancer, or in situ co-lon cancers; in situ cervical cancers/dysplasia; or breast carcinoma in situ).
Source: ClinicalTrials.gov (NCT06308510). StuddyBuddy aggregates publicly available trial information.